利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

33 条记录 (耗时 0.028 秒)

    Novel MAO-A inhibitors
    6.
    发明申请
    Novel MAO-A inhibitors 审中-公开
    新型MAO-A抑制剂

    公开(公告)号：US20090069313A1

    公开(公告)日：2009-03-12

    申请号：US11896902

    申请日：2007-09-06

    申请人： Debendranath Dey ,  Gajendra Singh ,  Partha Neogi ,  Uma Ramachandran ,  Chithra Santhanagopalan

    发明人： Debendranath Dey ,  Gajendra Singh ,  Partha Neogi ,  Uma Ramachandran ,  Chithra Santhanagopalan

    IPC分类号： A61K31/5377 ,  C07D277/16 ,  A61K31/426 ,  C07D209/34 ,  A61P25/24 ,  A61P25/32 ,  A61P25/08 ,  A61P25/00 ,  A61P25/34 ,  A61P25/28 ,  A61K31/404 ,  C07D413/12 ,  A61K31/422

    CPC分类号： C07D277/36 ,  C07D209/34 ,  C07D277/34 ,  C07D413/12 ,  C07D417/12

    摘要： The present invention provides a new medical use for the compounds of the formula (I), their derivatives, analogs, tautomeric forms, stereoisomers, polymorphs, hydrates, solvates, pharmaceutically acceptable salts and compositions, metabolites and prodrugs thereof, as MAO-A inhibitors. Also included is a method for prophylaxis and treatment of mental disorders such as depression, in a mammal, comprising administering an effective amount of a compound of formula (I). These compounds are also effective in treating a disease, condition or disorder such as weight loss, obesity, bulimia, depression, bipolar disorders, psychoses, schizophrenia, behaviors, alcoholism, tobacco abuse, memory loss, Alzheimer's disease, dementia of aging, seizure disorders, epilepsy, attention deficit disorder, and Parkinson's disease, which is modulated by a cannabinoid receptor antagonist.

    摘要翻译： 本发明提供了作为MAO-A抑制剂的式（I）化合物，其衍生物，类似物，互变异构形式，立体异构体，多晶型物，水合物，溶剂合物，药学上可接受的盐和组合物，其代谢物和前药的新医学用途 。 还包括在哺乳动物中预防和治疗精神障碍如抑郁症的方法，包括施用有效量的式（I）化合物。 这些化合物在治疗疾病，病症或病症如体重减轻，肥胖，贪食症，抑郁症，双相性精神障碍，精神病，精神分裂症，行为，酒精中毒，吸烟，记忆丧失，阿尔茨海默病，老年痴呆，癫痫发作障碍 ，癫痫，注意力缺陷障碍和由大麻素受体拮抗剂调节的帕金森病。

    Heterocyclic diphenyl ethers
    8.
    发明授权
    Heterocyclic diphenyl ethers 有权
    杂环二苯醚

    公开(公告)号：US07781464B2

    公开(公告)日：2010-08-24

    申请号：US11359657

    申请日：2006-02-21

    申请人： Partha Neogi ,  Bishwajit Nag ,  Debendranath Dey ,  Abhijeet Nag ,  Birendra Kumar Bhattacharya ,  Vinod Kumar Singh ,  Surendradoss Jayakumar

    发明人： Partha Neogi ,  Bishwajit Nag ,  Debendranath Dey ,  Abhijeet Nag ,  Birendra Kumar Bhattacharya ,  Vinod Kumar Singh ,  Surendradoss Jayakumar

    IPC分类号： A61K31/426 ,  C07D277/04

    CPC分类号： C07D277/34 ,  C07D209/34 ,  C07D277/36 ,  C07D401/12 ,  C07D417/12

    摘要： The present invention relates to novel heterocyclic diphenyl ether and diphenyl amine compounds, derivatives, analogs, tautomeric forms, stereoisomers, polymorphs, hydrates, solvates, pharmaceutically acceptable salts and pharmaceutically acceptable solvates thereof and pharmaceutically acceptable compositions containing these singly or in combination. The compounds of the present invention are effective in lowering blood glucose, serum insulin, free fatty acids, cholesterol and triglyceride levels and are useful in the treatment and/or prophylaxis of diabetes. The compounds of the present invention are effective in treatment of obesity, inflammation, autoimmune diseases such as multiple sclerosis and rheumatoid arthritis and immunological diseases, including the treatment of cancer. Furthermore, the compounds are useful for the treatment of disorders associated with insulin resistance.

    摘要翻译： 本发明涉及新颖的杂环二苯醚和二苯胺化合物，衍生物，类似物，互变异构形式，立体异构体，多晶型物，水合物，溶剂化物，药学上可接受的盐和药学上可接受的溶剂合物以及含有这些单独或组合的药学上可接受的组合物。 本发明的化合物可有效降低血糖，血清胰岛素，游离脂肪酸，胆固醇和甘油三酯水平，并且可用于治疗和/或预防糖尿病。 本发明的化合物可有效治疗肥胖，炎症，自身免疫性疾病如多发性硬化和类风湿性关节炎以及免疫疾病，包括治疗癌症。 此外，这些化合物可用于治疗与胰岛素抵抗相关的疾病。

    Novel heterocyclic analogs of diphenylethylene compounds
    9.
    发明申请
    Novel heterocyclic analogs of diphenylethylene compounds 失效
    二苯基乙烯化合物的新型杂环类似物

    公开(公告)号：US20080293949A1

    公开(公告)日：2008-11-27

    申请号：US12078662

    申请日：2008-04-02

    申请人： Partha Neogi ,  Debendranath Dey ,  Satyanarayana Medicherla ,  Bishwajit Nag ,  Arthur Lee

    发明人： Partha Neogi ,  Debendranath Dey ,  Satyanarayana Medicherla ,  Bishwajit Nag ,  Arthur Lee

    IPC分类号： C07D277/14

    CPC分类号： C07D277/20 ,  C07D277/24 ,  C07D277/34

    摘要： Novel diphenylethylene compounds and derivatives thereof containing thiazolidinedione or oxazolidinedione moieties are provided which are effective in lowering blood glucose level, serum insulin, triglyceride and free fatty acid levels in animal models of Type II diabetes. The compounds are disclosed as useful for a variety of treatments including the treatment of inflammation, inflammatory and immunological diseases, insulin resistance, hyperlipidemia, coronary artery disease, cancer and multiple sclerosis.

    摘要翻译： 提供了含有噻唑烷二酮或恶唑烷二酮部分的新型二苯基乙烯化合物及其衍生物，其有效降低II型糖尿病动物模型中的血糖水平，血清胰岛素，甘油三酯和游离脂肪酸水平。 所述化合物被公开用于各种治疗，包括治疗炎症，炎症和免疫疾病，胰岛素抵抗，高脂血症，冠状动脉疾病，癌症和多发性硬化。

    Heterocyclic analogs of diphenylethylene compounds
    10.
    发明授权
    Heterocyclic analogs of diphenylethylene compounds 失效
    二苯基乙烯化合物的杂环类似物

    公开(公告)号：US07202366B2

    公开(公告)日：2007-04-10

    申请号：US10808519

    申请日：2004-03-25

    申请人： Bishwajit Nag ,  Debendranath Dey ,  Satyanarayana Medicherla ,  Partha Neogi

    发明人： Bishwajit Nag ,  Debendranath Dey ,  Satyanarayana Medicherla ,  Partha Neogi

    IPC分类号： A61K31/41 ,  C07D277/60

    CPC分类号： C07D277/20 ,  C07D277/24 ,  C07D277/34

    摘要： Novel diphenylethylene compounds and derivatives thereof containing thiazolidinedione or oxazolidinedione moieties are provided which are effective in lowering blood glucose level, serum insulin, triglyceride and free fatty acid levels in animal models of Type II diabetes. In contrast to previously reported thiazolidinedione compounds, known to lower leptin levels, the present compounds increase leptin levels and have no known liver toxicity. The compounds are disclosed as useful for a variety of treatments including the treatment of inflammation, inflammatory and immunological diseases, insulin resistance, hyperlipidemia, coronary artery disease, cancer and multiple sclerosis.

    摘要翻译： 提供了含有噻唑烷二酮或恶唑烷二酮部分的新型二苯基乙烯化合物及其衍生物，其有效降低II型糖尿病动物模型中的血糖水平，血清胰岛素，甘油三酯和游离脂肪酸水平。 与之前报道的已知降低瘦蛋白水平的噻唑烷二酮化合物相比，本发明化合物增加瘦素水平并且没有已知的肝脏毒性。 所述化合物被公开用于各种治疗，包括治疗炎症，炎症和免疫疾病，胰岛素抵抗，高脂血症，冠状动脉疾病，癌症和多发性硬化。